禮來Olomorasib藥物獲得FDA突破性療法認定

【禮來Olomorasib獲得美國FDA突破性療法認定】9月4日訊，禮來(LLY.N)藥物Olomorasib獲得美國FDA突破性療法認定，用於治療特定新診斷的轉移性KRASG12C突變肺癌。

最新市場快訊

::: Capital Securities Capital Inv. Cons. Capital Insurance Capital Asset Mgmt. Capital HK

Navigation About Governance Sustainable Fair Treatment Anti-Fraud Stakeholders Disclaimer Security Friendly Career ESG Initiatives

Futures Corporation:(02)2700-2888
B1, No. 97, Section 2, Dunhua South Road, Taipei City
Taichung Branch:(04)2319-9909
3F-6, No. 633, Sec. 2, Taiwan Blvd, Xitun Dist, Taichung City